Clinical Trials Logo
  1. Home
  2. Gastric Cancer Stage IV
  3. NCT04563975

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

Gastric Cancer Stage IV Clinical Trial

Official title:
Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial

Clinical Trial Summary

The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody (Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with advanced gastric cancer who failed first-line treatment.

Clinical Trial Description

54 patients who meet the inclusion criteria will receive Docetaxel (60-75mg/m2, every 3 weeks) or nab-Paclitaxel （125mg/m2，every 3 weeks）combined with Toripalimab( 240mg,every 3 weeks）for 4-8 cycles until the disease progresses or intolerable toxicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04563975
Study type Interventional
Source Wuhan Union Hospital, China
Contact Tao Zhang, Doctor
Phone (+86)18971656660
Email 1277577866@qq.com
Status Recruiting
Phase Phase 2
Start date July 2, 2020
Completion date May 30, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04592211 - Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS Phase 1/Phase 2
Recruiting NCT05301465 - Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
Active, not recruiting NCT06034964 - Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Active, not recruiting NCT04267549 - Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer Phase 2
Recruiting NCT06342427 - Stomach Cancer Exosome-based Detection
Terminated NCT04168931 - Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC Phase 2
Recruiting NCT03701373 - Maintenance Treatment With S-1 in Gastric Cancer Patients Phase 2
Recruiting NCT05319639 - Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Phase 1/Phase 2
Completed NCT03618758 - Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 Phase 1/Phase 2
Completed NCT03755440 - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. Phase 2
Completed NCT03159585 - To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors Phase 1